ALK and Alzheimer disease: EGFR, KRAS mutations, and ALK fusions were detected in 55.4%, 16.1%, and 8.9% of AD, respectively, but not in SqCC patients, whereas CDKN2A (34.4% vs 5.4%), KEAP1 (31.3% vs 3.6%), RB1 (15.6% vs 0%), and NFE2L2 (12.5% vs 0%) alterations were more enriched in SqCC patients.